Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
Trial details
- Registry ID
- NCT07425392
- Drugs studied
- 31-valent pneumococcal conjugate vaccine, PCV20
TrialRedline tracks 6 clinical trials sponsored by Vaxcyte, Inc.: 3 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationNCT07425392 | 31-valent pneumococcal conjugate vaccine, PCV20 | Completed | 2026-10-25Actual |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeNCT07365826 | 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok) | Completed | 2026-10-21Actual |
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49NCT07284654 | 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 | Completed | 2026-09-17Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsNCT06720038 | 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL of the low dose VAX-31 and 1 more | Active not recruiting | 2027-12Estimated |
| Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsNCT05844423 | 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24, 0.5 ml dose of PCV20 | Completed | 2025-08-25Actual |
| Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older AdultsNCT05297578 | 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine | Completed | 2023-02-15Actual |
Names as written in the registry records.
NCT07425392 · Vaxcyte, Inc.
Before: Estimated. After: Actual.
Before: Mar 2027. After: 25 Oct 2026.
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: Mar 2027. After: 21 Oct 2026.
Before: Active not recruiting. After: Completed.
NCT07284654 · Vaxcyte, Inc.
Before: Estimated. After: Actual.
Before: Jan 2027. After: 17 Sep 2026.
Before: Active not recruiting. After: Completed.
NCT06720038 · Vaxcyte, Inc.
Before: 905 participants (actual). After: 900 participants (actual).
NCT07425392 · Vaxcyte, Inc.
Before: Estimated. After: Actual.
Before: 720 participants (planned). After: 752 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT07284654 · Vaxcyte, Inc.
Before: Estimated. After: Actual.
Before: 4000 participants (planned). After: 4049 participants (actual).
Before: Recruiting. After: Active not recruiting.
Before: Estimated. After: Actual.
Before: 1300 participants (planned). After: 1390 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT06720038 · Vaxcyte, Inc.
Before: Estimated. After: Actual.
Before: 900 participants (planned). After: 905 participants (actual).
Before: Recruiting. After: Active not recruiting.